Science and Research

P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057: Track: Immunotherapy

  • Gralla, R. J.
  • Spigel, D.
  • Bennett, B.
  • Taylor, F.
  • Penrod, J. R.
  • Derosa, M.
  • Dastani, H.
  • Orsini, L.
  • Mathias, C.
  • Reck, M.
Publication details
DOI: 10.1016/j.jtho.2016.08.117
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Pages: S247 
Number: 10S
Work Type: Other
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 27676580
See publication on PubMed

DZL Engagements

chevron-down